New prostate cancer risk groups by PSMA-PET (PPP3): an international, retrospective, registry-based cohort study.
Karpinski MJ, Civan C, Rauscher I, Güven O, Eiber M, Hoberück S, Miederer M, Bundschuh RA, Hölscher T, Calais J, Theus L, Nguyen AT, Scholtissek H, Lapa C, Di Giorgio A, Farolfi A, Ufton D, Drzezga A, Kunikowska J, Pełka K, Evangelista L, Bauman G, Alçın G, Beintner-Skawran S, Rohani MFM, Miksch J, Hüsing A, Kesch C, Herrmann K, Stuschke M, Umutlu L, Gafita A, Hofman MS, Hope TA, Goffin K, Kind F, Pizzuto DA, Soeterik TFW, Kömek H, Emmett L, Vondrak A, Pinter T, Lanfranchi F, Bauckneht M, Unterrainer LM, Holzgreve A, Bjartell A, Trägårdh E, Rasul S, Miszczyk M, Bögemann M, Rodriguez SantAnna Jauregui N, Schäfers M, Rahbar K, Hadaschik BA, Fendler WP; PROMISE Registry Group.
Karpinski MJ, et al. Among authors: evangelista l.
Lancet Oncol. 2026 Apr;27(4):480-490. doi: 10.1016/S1470-2045(26)00016-1. Epub 2026 Mar 9.
Lancet Oncol. 2026.
PMID: 41819113
Free article.